- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02914704
Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)
MRI-guided high intensity focused ultrasound (MRI-HIFU) has been proven to be a safe and effective method in treating uterine fibroids and also adenomyosis. However, systematic studies on the effect of this treatment on factors affecting fertility are still lacking. Also quite little is known about body's systemic response to MRI-HIFU. Thus the aim of this study is to obtain more information on the systemic response of the body to the HIFU-treatment when treating non-malignant disease as well as to study the effect of MRI-HIFU on factors affecting fertility. Women with symptomatic uterine fibroids or adenomyosis suitable for MRI-HIFU treatment are recruited to this study. The severity of symptoms will be assessed with UFS-QoL and the same questionnaire will also be used in follow-up 3, 6 and 12 months after treatment. Blood, urine and endometrium samples will be collected pre- and postoperatively and during follow-up 3, 6 and 12 months after the treatment. From these samples detailed analysis of the immunological, inflammatory and hormonal response will be performed. As this is the first study in Finland of treating uterine fibroids and adenomyosis using MRI-HIFU, also a report about the efficacy of the MRI-HIFU in treating the uterine disorders will be published, and a key tool in assessing the treatment outcome would be the UFS-QoL questionnaire.
Also new methods for improving patient selection as well as treatment efficacy will be evaluated in this study.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kirsi M Joronen, PhD
- Email: kirsi.joronen@tyks.fi
Study Locations
-
-
-
Turku, Finland, 20521
- Recruiting
- Turku University Hospital
-
Contact:
- Kirsi M Joronen, MD PhD
- Phone Number: +35823130561
- Email: kirsi.joronen@tyks.fi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- BMI < 35
- Premenopausal
- Uterine size <20 gw
- Willingness to participate to the research
- Uterine fibroids with typical symptoms
- Maximum of 4 treated fibroids
- Dominant fibroid >2.5cm
- >50% of the fibroid is treatable
Exclusion criteria
- Unspecified pelvic tumours or ovarian masses, PID
- Major corrective surgery to uterus (simple myomectomy excluded)
- Major uterine anomalies
- Unability to calculate the volume of uterine fibroids
- Marked uterine calcification
- Marked scarring of the lower abdomen
- Suspicion of malignancy
- Marked general health problem contraindicating MRI
- Claustrophobia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients treated with MRI-HIFU
|
Treatment of uterine fibroids with MRI-HIFU
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Technical efficacy of HIFU for treatment of uterine fibroids as assessed by a change in the Symptom Severity Score
Time Frame: 12 months after treatment
|
12 months after treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kirsi M Joronen, PhD, Turku University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GYN-HIFU
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenomyosis
-
Shanghai First Maternity and Infant HospitalUnknownAdenomyosis of Uterus
-
Mansoura UniversityCompletedthe Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine AdenomyosisEgypt
-
Assiut UniversityUnknown
-
Ain Shams Maternity HospitalUnknown
-
Woman's Health University Hospital, EgyptCompleted
-
University College, LondonRecruiting
-
Mersin UniversityCompleted
-
Queen Mary Hospital, Hong KongUnknown
Clinical Trials on MRI-HIFU
-
Sana BoudabbousRecruitingMRI | Pain | Bone Metastases | RadiotherapySwitzerland
-
Sunnybrook Health Sciences CentreSunnybrook Research Institute; Arrayus Technologies Inc.Active, not recruiting
-
Philips HealthcarePhilips Medical SystemsCompletedUterine FibroidsKorea, Republic of, Netherlands, France, Germany
-
Hospices Civils de LyonActive, not recruiting
-
Hospices Civils de LyonActive, not recruiting
-
Imperial College LondonImperial College Healthcare NHS TrustWithdrawnCervical Cancer | Ovarian Cancer | Rectal Cancer | Endometrial Cancer | Vaginal CancerUnited Kingdom
-
Hospital de Transplante Doutor Euryclides de Jesus...UnknownProstate Cancer | Prostate Adenocarcinoma | Transrectal High Intensity Focused UltrasoundBrazil
-
TheraclionGroupe Hospitalier Pitie-Salpetriere; Hôpital Saint Louis ParisTerminatedAutonomous Hyperfunctioning Thyroid NodulesFrance
-
TheraclionCompleted